144-11-6
Chemical Structure
Trihexyphenidyl
- CAS No.: 144-11-6
- Formula:C20H31NO
- Molecular Weight:301.47
IUPAC Name: 1-cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
InChIKey: HWHLPVGTWGOCJO-UHFFFAOYSA-N
SMILES: OC(C1=CC=CC=C1)(C2CCCCC2)CCN3CCCCC3
Biological Activity: Trihexyphenidyl is a selective and orally active M1 muscarinic receptor antagonist with an IC50 of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease.[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trihexyphenidyl | Trihexyphenidyl is a selective and orally active M1 muscarinic receptor antagonist with an IC50 of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease.. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trihexyphenidyl-d5 | Trihexyphenidyl-d5 is deuterium labeled Trihexyphenidyl (HY-B1277A). Trihexyphenidyl is a selective and orally active M1 muscarinic receptor antagonist with an IC50 of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease.. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Jabbari B, et al. Treatment of movement disorders with trihexyphenidyl[J]. Movement disorders: official journal of the Movement Disorder Society, 1989, 4(3): 202-212. [Content Brief]
- [2]. Giachetti A, et al. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol. 1986;89(1):83-90. [Content Brief]
- [3]. Takahashi S, et al. The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. J Neurol Sci. 1999;167(1):56-61. [Content Brief]
Keywords
